Overview

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to collect information from subjects with osteoporosis regarding their experience using the Forteo B Pen to self-administer teriparatide in the community setting. Information collected during this study will be used to assess the need for changes to the Forteo B-Pen User Manual and patient educational tools. Additionally, the information generated from patients during this trial will be reviewed to assess the acceptability of the Forteo B Pen for commercial launch.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Teriparatide